Despite setbacks, Sarepta’s gene therapy pipeline and market leadership in DMD present a high-risk, high-reward setup. Read ...

Despite Walmart's strengths, the risk/reward is poor at current prices. Click here to see why WMT stock is a Sell.

Much has been said about decoupling rare earth supply chains from China or from Chinese influence in order to reduce reliance on any one country for whatever reason.